Drugs to 'transform' fragile X syndrome market named by GlobalData

By 2030, GlobalData has predicted that promising pipeline drugs Zygel (cannabidiol gel), zatolmilast, trofinetide, and acamprosate calcium SR will offer new treatment options for people with Fragile X Syndrome (FXS), a rare genetic disorder that is the leading cause of inherited intellectual disability.

The data and analytics company expects these products to help propel the growth of the FXS market, adding around $23.3 million to its value by 2030.

"A new dynamic market with a variety of options for patients"Christie Wong, neurology analyst at GlobalData, said: “There are a number of exciting pipeline drugs for the treatment of FXS that will transform the market over the next decade. For example, GlobalData expects Zynerba Pharmaceuticals’ (Nasdaq: ZYNE) Zygel will be the first to market, with a primary completion date for its Phase III trial expected in September 2023. Zygel could offer an important therapeutic option for patients who are the most severely impacted with FXS and could bring in sales of $18.1 million by 2030.